Patients @ to @ years of age with fasting low-density lipoprotein cholesterol ( LDL-C ) @ and < @ mg/dl and Framingham risk scores@ % were randomized ( @:@:@:@:@:@ ) to oral placebo and subcutaneous ( SC ) placebo biweekly ; oral placebo and SC placebo monthly ; ezetimibe and SC placebo biweekly ; ezetimibe and SC placebo monthly ; oral placebo and evolocumab @ mg biweekly ; or oral placebo and evolocumab @ mg monthly .